The reiteration of a Buy rating and maintenance of a $41 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially drive Syndax Pharmaceuticals' stock price upwards in the short term. Analyst ratings, especially from well-regarded firms, often influence investor sentiment and can lead to price movements.